30519-00-7

Upstream product

• 637-89-8 4-sulfanylphenol 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 59621-41-9 [4-(4-chlorophenoxy)phenylsulfanyl]acetic acid ethyl ester 
• 287201-65-4 (4-oct-2-ynyloxyphenylsulfanyl)acetic acid ethyl ester 
• 239797-50-3 [4-(3-methylbutoxy)phenylsulfanyl]acetic acid ethyl ester 
• 239797-56-9 [4-(2-ethylbutoxy)phenylsulfanyl]acetic acid ethyl ester 
• 872116-65-9 ethyl {[4-(benzyloxy)phenyl]thio}acetate 
• 42580-38-1 2-(4-hydroxyphenylthio)acetic acid 
• 1176739-72-2 3-(4-Carboxymethylsulfanylphenoxymethyl)thiophene-2-carboxylic acid 
• 1269425-36-6 2-(4-(3-(4-amino-2,3-dimethylphenoxy)propoxy)phenylthio)acetic acid 
• 1269425-34-4 ethyl 2-(4-(3-(4-amino-2,3-dimethylphenoxy)propoxy)phenylthio)acetate 
• 1269425-32-2 ethyl 2-(4-(3-(4-(tert-butoxycarbonylamino)-2,3-dimethylphenoxy)propoxy)phenylthio)acetate 
• 1269425-30-0 C₁₃H₁₈O₄S 
• 1176739-70-0 methyl 3-(4-ethoxycarbonylmethylsulfanylphenoxymethyl)thiophene-2-carboxylate 
• 1186435-83-5 ethyl 2-(4-(3-(2,3-dimethylphenoxy)propoxy)phenylthio)acetate 
• 565461-18-9 1-(4-methoxybenzyl)-4-[4-(4-chlorophenoxy)benzenesulfonyl]piperidine-4-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

3-PHENYLSULPHONYL-QUINOLINE DERIVATIVES AS AGENTS FOR TREATING PATHOGENIC BLOOD VESSELS DISORDERS

The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessles. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.

Blood-Brain Barrier Permeable and NO-Releasing Multifunctional Nanoparticles for Alzheimer’s Disease Treatment: Targeting NO/cGMP/CREB Signaling Pathways

The development of novel therapeutic strategies for combating Alzheimer’s disease (AD) is challenging but imperative. Multifunctional nanoparticles are promising tools for regulating complex pathological dysfunctions for AD treatment. Herein, we construct

Design, synthesis and biological evaluation of oxime lacking Psammaplin inspired chemical libraries as anti-cancer agents

In this study, we attempted the chemical simplification of Psammaplin (PsA), while retaining its activity in vitro. Inspired by the previous Structure Activity Relationship (SAR) studies on various PsA analogues and relying on the fact that oxime is metabolically unstable, we initially designed and synthesized a diverse library of PsA analogues and evaluated for cytotoxic activity. Among 32 compounds of Psammaplin analogues synthesized, the compound 10b was almost equally active as parent Psammaplin in vitro.

Rhodium-Catalyzed Rearrangement of S/Se-Ylides for the Synthesis of Substituted Vinylogous Carbonates

An efficient rhodium-catalyzed unprecedented oxa-[2,3]-sigmatropic rearrangement of sulfur ylide derived from α-thioesters/ketones and diazo carbonyl compounds has been accomplished for the synthesis of various sulfur-tethered vinylogous carbonates in good to excellent yields. Important features of the developed reaction include wide functional group tolerance, excellent chemo- and regioselectivity, and efficient rearrangement involving the carbonyl motif. The present reaction also equally works well with α-selenoesters for the synthesis of seleno-containing vinylogous carbonates.

Identification of 2-mercaptohexanoic acids as dual inhibitors of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1

5-Lipoxygenase (5-LO) and microsomal prostaglandin E2 synthase (mPGES)-1 are key enzymes in the biosynthesis of leukotrienes and prostaglandin (PG)E2, respectively, and are considered as valuable targets for the treatment of inflamma

GPR120 RECEPTOR AGONISTS AND USES THEREOF

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

PIPERIDINE DERIVATIVE

The present invention provides a compound a piperidine derivative having excellent histamine receptor antagonistic action, which is useful as active ingredients of a pharmaceutical composition, especially an antihistamine. The piperidine derivative of the

ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF

Aryl GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

Functionalization of fatty acid mimetics for solid-phase coupling and subsequent target identification

Fatty acid mimetics such as pirinixic acid (PA) derivatives and 2-(phenylthio)alkanoic acid derivatives are drug-like small molecules with an interesting pharmacological profile. Previously, we have characterized PA derivatives (e.g., 1) as dual agonists

GPR120 RECEPTOR AGONISTS AND USES THEREOF

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.